eISSN: 1731-2531
ISSN: 1642-5758
Anaesthesiology Intensive Therapy
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees

Journal integrated with

integrated with publons
5/2020
vol. 52
 
Share:
Send email
Share:
abstract:
Original paper

Clinical outcomes of high-flow nasal cannula in COVID-19 associated postextubation respiratory failure. A single-centre case series

Francesca Simioli
1
,
Anna Annunziata
1
,
Gerardo Langella
1
,
Giorgio E. Polistina
1
,
Maria Martino
1
,
Giuseppe Fiorentino
1

  1. Department of Respiratory Pathophysiology, Monaldi-Cotugno Hospital, Naples, Italy
Anaesthesiol Intensive Ther 2020; 52, 5: 373–376
DOI: https://doi.org/10.5114/ait.2020.101007
Online publish date: 2020/11/18
View full text Get citation
 
PlumX metrics:
Introduction
A high-flow nasal cannula (HFNC) is an alternative device for oxygena­tion, which improves gas exchange and reduces the work of breathing. Postextubation respiratory failure causes increased morbidity and mortality. HFNC has been widely employed during the COVID-19 pandemic. The purpose of this paper is to report a single-centre experience on the effectiveness and safety of HFNC in weaning COVID-19 patients.

Material and methods
Nine patients showed severe acute respiratory failure and interstitial pneumonia due to SARS-CoV-2. After mechanical ventilation (5 Helmet CPAP, 4 invasive mechanical ventilation), they were de-escalated to HFNC. Settings were: 34–37°C, flow from 50 to 60 L min-1. FiO2 was set to achieve appropriate SpO2.

Results
Nine patients (4 females; age 63 ± 13.27 years; BMI 27.2 ± 4.27) showed a baseline PaO2/FiO2 of 109 ± 45 mm Hg. After a long course of ventilation all patients improved (PaO2/FiO2 336 ± 72 mm Hg). Immediately after initiation of HFNC (2 hours), PaO2/FiO2 was 254 ± 69.3 mm Hg. Mean ROX index at two hours was 11.17 (range: 7.38–14.4). It was consistent with low risk of HFNC failure. No difference was observed on lactate. After 48 hours of HFNC oxygen therapy (day 3), mean PaO2/FiO2 increased to 396 ± 83.5 mm Hg. All patients recovered from respiratory failure after 7 ± 4.1 days.

Conclusions
HFNC might be helpful in weaning COVID-19 respiratory failure. Effectiveness and comfort should be assessed between 2 and 48 hours. Clinical outcomes, oxygenation, and ROX index should be considered, to rule out the need for intubation. Further evidence is required for firm conclusions.

keywords:

ventilation, weaning, COVID-19, high-flow nasal cannula, postextubation respiratory failure, ROX index
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.